SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Reported institutional tokenization developments are driving attention, particularly NYSE/ICE testing Avalanche for 24/7 on-chain securities trading, alongside broader RWA adoption and upcoming network upgrades. Bulls view the move as evidence of institutional validation and altcoin rotation, while skeptics argue it lacks volume and may be another short-lived pump.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Anticipation of Aerodromes Ethereum mainnet expansion and related Aero/Velodrome merger, alongside its predictive-allocation upgrade and role in Base tokenized-stock liquidity, is driving attention. Traders are largely bullish on broader utility, buybacks and accumulation, while skeptics cite rollout delays, token supply concerns and speculative hype around a potential breakout.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Anticipation of Arcturus ARCT-810 Phase 2 OTC deficiency data and regulatory-path update is driving attention, alongside a broader platform presentation covering its mRNA liver therapeutics. Traders are optimistic that favorable results could support Phase 3 advancement and partnerships, while short sellers and skeptics question whether the gains are driven mainly by speculation and short covering.

Injective is an interoperable Layer 1 blockchain designed for DeFi applications. It provides developers with on-chain financial infrastructure modules to build dApps such as decentralized exchanges, prediction markets, and lending protocols. Its decentralized cross-chain bridging infrastructure offers compatibility with most blockchains, including EVM chains like Ethereum and non-EVM chains like Solana.

Injective

Attention is centered on Injectives reported Solana launch and a staking-enabled ETF filing update, alongside its broader tokenization and regulated-finance push. Traders are largely bullish and debating whether the rally reflects genuine institutional flows or a short squeeze, while some warn it could be a temporary sell-the-news move.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Updates to Greenwich LifeSciences FLAMINGO-01 Phase 3 breast-cancer vaccine trialincluding broader HLA enrollment, an expanded study design and revised interim-analysis timingare driving attention, alongside discussion of encouraging open-label recurrence data. Traders are split between viewing the changes as de-risking the program and improving partnership prospects, while others remain concerned about delayed results, financing needs and dilution risk.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Speculative breakout hopes amid a broader crypto-market rebound are driving attention, with traders citing improving technical signals, rising volume and potential Doge-1 or regulatory catalysts. The community remains divided between bulls expecting a move higher and skeptics warning of resistance, weak momentum and another selloff.

Chip

Attention is centered on USD.AIs AI-infrastructure thesis, with traders highlighting GPU-backed lending, reported financing activity and the tokens role in funding compute. The community is sharply divided: bulls see an early, accumulating real-world utility play, while bears point to heavy volatility, supply dilution, unclear buyback details and persistent selling as evidence of a potential pump-and-dump.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDashs quarterly results and forward outlook are driving attention, with traders focusing on strong order growth and improving profitability despite a mixed share-price reaction. Bulls view the operating momentum as supportive, while bears cite the premium valuation, weaker GAAP earnings, and concerns that delivery competition and AI-driven ordering could pressure margins.

Daily surprises, near and far. Your source for travel inspiration and more. Travel moves you!

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Reports that Paramount Skydance is in advanced settlement talks with California officials over the antitrust lawsuit challenging its Warner Bros. Discovery acquisition have driven renewed merger optimism and strong after-hours interest. Traders largely view a settlement as bringing the deal closer to completion, though some caution that negotiations remain unresolved and the transaction could still face legal or structural concessions.

VeChain is a public Layer-1 blockchain designed for real-world applications. Founded in 2015, its VeChainThor network supports enterprise and consumer use cases involving supply chains, product provenance, sustainability, digital product passports, tokenized incentives and verifiable data.  VeChainThor combines EVM-compatible smart contracts with a dual-token model, native fee delegation and multi-clause transactions. VET is the network’s native asset and staking collateral, while VTHO is used to pay transaction fees and execute smart contracts.  VeChain’s ecosystem includes VeBetter, an app platform that rewards verified positive actions; StarGate, its NFT-based staking platform; VeWorld, its self-custody wallet; and VeWorld.ai, its AI-agent platform. In its April 2026 roadmap, VeChain reported that VeBetter had reached 5.3 million users, more than 50 live applications and over 50 million verified actions.  VeChain has also worked with organizations including Walmart China, DNV, PwC, Boston Consulting Group and UFC across enterprise, sustainability and consumer initiatives.

Vechain

VeChains Interstellar (VIP-255) mainnet upgrade is the dominant catalyst, with traders highlighting expanded Ethereum compatibility, developer tooling, and the broader Renaissance roadmap as reasons for the recent breakout and renewed attention. The community is split between bullish holders expecting stronger adoption and skeptics arguing the upgrade has not yet translated into meaningful price performance amid broader crypto-market weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Verastem Stock Skyrockets 121% in 3 Months: Here Is Why

VSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances across key cancer studies.

Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and...

Verastem Oncology to Participate in Upcoming September Investor Conferences

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8 in Boston and...

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Verastem (VSTM) delivered earnings and revenue surprises of +23.91% and +73.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business progress. The second quarter marked...

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.94% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +3.23% and +60.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of -5.00% and +6.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been dosed in the TARGET-D 203 Phase 2 registration-directed trial evaluating VS-7375, an investigational...

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

VSTM Stock Climbs After-Hours As FDA Grants Fast Track To Lung Cancer Drug — Retail Eyes The Next Keytruda 

Equity

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

VSTM Verastem Inc

Fundamentals

Latest VSTM News